GSK1795091 (CRX-601; GSK-1795091) is a novel and potent Toll-like receptor 4 (TLR4) agonist with antitumor activity. TLR4 is a member of the TLR family tha plays a key role in the activation of innate immunity against pathogens. As an immunologic stimulator, it can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. GSK1795091 is being studies in clinical trials for the treatment of cancer. GSK1795091 binds to and activates TLR4, thereby stimulating dendritic cells (DCs), monocytes and macrophages. This activation results in the production of pro-inflammatory cytokines, including interferon gamma (IFN-g), tumor necrosis factor-alpha (TNF-a) and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and, upon co-administration of a vaccine containing tumor-associated antigens (TAAs), activates a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing those TAAs.

纯度：≥98%

CAS：1233589-81-5